Multiple Myeloma

10 protocols meet the specified criteria.

  • 68284528MMY4006

    Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

  • BB2121-EAP-001

    Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

  • CA057-008

    A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  • EAA173

    Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)

  • JCAR017-EAP-001

    Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

  • KT-US-472-0141

    Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication

  • NCBP6637-01

    A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

  • SNDX-5613-0708

    A Phase 1, Open-Label, Dose-escalation, and Dose-Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin1 (NPM1), and Nucleoporin 98 (NUP98) Genes